AiCure

Creabilis

Creabilis names Moukheibir to board of directors

Thursday, February 28, 2013 02:33 PM

Creabilis, a late clinical stage European biotechnology company specializing in developing treatments in dermatology, inflammation and pain, has appointed Catherine Moukheibir to its board of directors.

More... »


Creabilis appoints Simon Russell as chief business officer

Friday, May 4, 2012 04:43 PM

Creabilis, a European biotech specializing in the development of treatments for dermatology, inflammation and pain, has appointed Simon Russell as chief business officer.

More... »


Creabilis begins phase IIb trial of CT327 in psoriasis

Wednesday, March 14, 2012 09:25 AM

Creabilis, a European biotechnology company specializing in dermatology, inflammation and pain, has initiated a phase IIb global clinical trial of its lead product CT327 in patients with psoriasis vulgaris.

More... »

Creabilis raises $20M in Series B funding

Tuesday, October 4, 2011 12:50 PM

Creabilis, a clinical stage European biotechnology company, has raised $20 million in a Series B funding round led by Abbott Biotech Ventures. Existing investors Neomed and Sofinnova Partners, as well as private Italian investors, joined the round. The new funds will be used to finance the development of the company's first-in-class treatments, including its lead product CT327 to the end of phase II.

More... »

Creabilis expands management team

Thursday, August 18, 2011 10:52 AM

Creabilis has expanded its senior management team. Alex Leech joins as vice president, head of finance and operations, James Sandy as senior vice president, head of development, and Peter Spargo as senior vice president of chemistry manufacturing and controls.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs